Amgen (AMGN) Tops Q2 EPS by 69c, Beats on Revenue; Offers FY26 Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $6.29, $0.69 better than the analyst estimate of $5.60. Revenue for the quarter came in at $10.1 billion versus the consensus estimate of $9.43 billion.

GUIDANCE:

Amgen sees FY2026 EPS of $22.30-$23.50, versus the consensus of $22.35. Amgen sees FY2026 revenue of $38.2-39.4 billion, versus the consensus of $37.7 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15